EGFR mutation – Medxy AI

AI news Oncology Pathology & Lab Medicine

Precision Oncology Meets Artificial Intelligence: Navigating Ancestry-Associated Variability in Digital Pathology for EGFR Prediction

By MedXY 02/20/2026

This review evaluates the generalizability of AI pathology models in predicting EGFR mutations, highlighting significant performance variations across genetic ancestries and specimen types, and their role in clinical triage.

news Oncology Respiratory

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

By MedXY 02/19/2026

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, with a manageable safety profile.

Dermatology news Oncology

Activating EGFR L858R Variants Linked to Syndromic Generalized Acanthosis Nigricans and Pulmonary Risk: A New Clinical Entity

By MedXY 01/27/2026

This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manifestations.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

Clinical Updates news Oncology Specialties

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.